Open AccessSuccessful ixazomib treatment for relapsed and refractory acute myeloid leukemia transformed from myelodysplastic syndrome
Author(s) -
Oka Satoko,
Ono Kazuo
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.4287
Subject(s) - medicine , azacitidine , ixazomib , myeloid leukemia , oncology , refractory (planetary science) , myelodysplastic syndromes , bone marrow , leukemia , bortezomib , myeloid , cancer research , multiple myeloma , carfilzomib , dna methylation , gene , physics , astrobiology , biochemistry , gene expression , chemistry
Elevated NF‐kB levels have been identified in primitive bone marrow cells from patients with MDS/AML, suggesting NF‐kB as a therapeutic target in MDS/AML. We herein describe an MDS patient ineligible for SCT who, following treatment with azacitidine and bortezomib, transformed to leukemia, but maintained complete remission after monotherapy with ixazomib.